The Covid Era Tech Promises To Reinvent Cancer Treatment
Express News | Merck has completed the acquisition of Tongrun Biomedical's cell depletion therapy investigational drug CN201.
Merck to Post 3Q Charge of About 28c/Share on Curon Deal >MRK
Express News | Merck & Co Inc - Recording Pre-Tax Charge of $750 Million, or $0.28 per Share
Express News | Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, Cn201, From Curon Biopharmaceutical
Merck & Co., Inc. (MRK) Projects 21% Upside With $140 Price Target as Keytruda and New Vaccines Drive Growth